|
Andrew Ment’s practice focuses on mergers and acquisitions and private equity transactions. Mr. Ment’s M&A experience includes public and private acquisitions and divestitures, leveraged buy-outs, “going private” transactions and joint ventures. Mr. Ment also practices in the area of corporate finance, where his experience includes syndicated lending, royalty sales & financings, registered offerings, and private placements.
Representative Matters
- Forest Laboratories, Inc. in its $1.2 billion acquisition of Clinical Data, Inc. and its $357 million acquisition of the U.S. patents and other US and Canadian intellectual property related to Bystolic®.
- eScreen, Inc. in its sale to Alere, Inc. for $270 million upfront and up to $70 million in contingent payments.
- Bristol-Myers Squibb Company in its acquisition of Amira Pharmaceuticals for $325 million upfront and up to $150 million in contingent payments.
- Procter & Gamble in the $3.1 billion sale of its pharmaceuticals business to Warner-Chilcott.
- Snow Phipps Group in its acquisition of Service Champ, Inc. and in its acquisition of Acentia (formerly ITSolutions) and multiple follow-on acquisitions by the Acentia portfolio company.
- Northwestern University in the sale of a portion of its worldwide royalty interest in Lyrica for $700 million.
- Oregon Steel Mills, Inc. in its $2.3 billion merger into Evraz Group S.A.
- Abbott Laboratories in its $3.7 billion acquisition of Kos Pharmaceuticals, Inc.
- Kerr-McGee Corporation in its $18 billion merger into Anadarko Petroleum Corporation.
Previous Experience
- Economic Consulting Services Inc., Staff Economist (1993-1995)
Honors and Rankings
- Legal 500 US, Mergers, Acquisitions & Buyouts - M&A (2013)
|